January 2019 – Ramizol® safe in rats
December 2018 – Boulos & Cooper Pharmaceuticals is delighted to announce that the Defence Materials Technology Centre (DMTC) is supporting it manufacturing efforts to scale up its antibiotic, Ramizol®, in collaboration with CSIRO.
August 2018 – Boulos & Cooper Pharmaceuticals signs $685,000 research collaboration deal with the Telethon Kids Institute in Perth, Western Australia.
August 2018 – Curtin FM asks CEO of Boulos & Cooper Pharmaceuticals, why pharmaceutical companies are abandoning antibiotic research.
July 2018 – Boulos & Cooper Pharmaceuticals welcome Professor John Turnidge to its Board of Directors.
June 2018 – Today the 20th of June is World Refugee Day. Our CEO talks to ABC Radio Perth about his journey as a refugee from Sudan.
June 2018 – Ramizol® active against fidaxomicin, metronidazole and vancomycin resistant C. difficile strains isolated from US clinics
May 2018 – Professor Wood AO and Professor Wilks FTSE join the board
Boulos & Cooper Pharmaceuticals is delighted to welcome Professor Fiona Wood and Professor Andrew Wilks to its Board of Directors.
April 2018 – CEO talks to Channel 9 News
CEO, Dr Ramiz Boulos, talks to Channel 9 News about the antibiotic cow.
April 2018 — Improved bioavailability and sustained release of Ramizol®
March 2018 – Mrs Chloe Cooper steps down
After 4 years on the Board, Mrs Cooper has stepped down as a Director of Boulos & Cooper Pharmaceuticals as the company moves on to the next phase of growth. Mrs Cooper was a founding Director and played a key role in the early stages of the company through her strategic and organisational skills. We thank her for her efforts and wish her all the best.
March 2018 – Antibiotic combination patent enters National Phase
Boulos & Cooper Pharmaceuticals has filed National Phase for its antibiotic therapy patent in the top 10 pharmaceutical markets. The patent claims combinations of Boulos & Cooper Pharmaceutical drugs and commercial antibiotics.
March 2018 – CEO talks to 6PR Radio
Dr Boulos speaks to 6PR Radio about the new class of antibiotics Boulos & Cooper Pharmaceuticals is developing.
February 2018 – Patent enters National Phase
Boulos & Cooper Pharmaceuticals has filed National Phase for its Synthesis patent in the following jurisdictions: Australia, Brazil, Canada, China, EU, India, Japan, Russia, South Korea and the USA. The patent claims a highly efficient synthetic route for Boulos & Cooper new class of antibiotics.
January 2018 – Sponsor of the ASBTE 2018
We are delighted to be a sponsor of The Australian Society of Biomaterials and Tissue Engineering Conference in Western Australia. As a local company, we are committed to playing a role in this exciting field.
January 2018 – Superbug drug in Perth firm’s sight
We feature in The West on our new class of antibiotics. Boulos & Cooper Pharmaceuticals’ antibiotic drugs address pathogens on the CDC Urgent Threat list.
December 2017 – Presenting at Biotech Showcase 2018
We are presenting at the Biotech Showcase 2018 in San Francisco. Join us to learn more about Boulos & Cooper Pharmaceuticals and our anti-infective programs.
Wednesday, January 10, 2018 at 2:15 PM at the Franciscan – C (Ballroom Level).
October 2017 – Appointment of Chairman and Consultant
It is with delight we announce the appointment of Grant Pestell as Chairman and the appointment of Claire Poll as an Adviser. We are very pleased to have such talent join our mission as we move on to the next phase of company growth and look forward to learn from their invaluable experience.
October 2017 — Come learn about us
We are presenting at Ausbiotech Invest 2017 in Melbourne on the 24th. Come hear about our antibiotic programs.
November 2016 — Boulos & Cooper Pharmaceuticals requests US FDA pre-IND meeting
August 2016 — Second generation of antibiotics for the treatment for Gram-negative bacteria
August 2016 — We are excited to be presenting at the Pitch & Partner session at the AMR Congress in Washington DC next month.
May 2016 — New treatment for C. difficile associated disease
April 2016 — We have moved!
Boulos & Cooper Pharmaceuticals has relocated to Perth, Western Australia. We have moved into the Stirling Business Centre on Delawney Street, Balcatta.
March 2016 — New antibiotic for the treatment of acne
February 2016 — Hear about our preclinical development
We are presenting at the upcoming Bio Asia conference in Tokyo on the oral antibiotic Ramizol® for the treatment of CDAD, and Zolav® antibiotic cream for the treatment of acne vulgaris.
August 2015 — Come learn about us
We are attending ICAAC/ICC 2015 in San Diego from the 17th to the 21st of September. If you would like to learn more about us, come visit us at Booth 925.
May 2015 — New Director appointed to Board
Boulos & Cooper Pharmaceuticals is thrilled to have Mr Alfonso Pelliccione join our Board of Directors. Mr Pelliccione is the Managing Director of the Ampac group of companies and brings with him over 30 years of business experience.
May 2015 — US patent granted
US patent (US9023892 B2) licensed exclusively to Boulos & Cooper Pharmaceuticals has been granted.
February 2015 — CEO talks to John Ross from The Australian
February 2015 — Medical Xpress interviews CEO about the new class of antibiotics
February 2015 — CEO talks to ABC News radio on new discovery
February 2015 — Novel antibiotics show promise in fight against superbugs
February 2015 — New antibiotic paper published
September 2014 — Pre-clinical testing funded
Boulos & Cooper Pharmaceuticals has successfully closed its first round of funding for pre-clinical testing.
September 2014 — Sponsorship deal for Tech Transfer Summit Australia 2014
July 2014 — Australian patent granted
Australian patent (AU2010336009) licensed exclusively to Boulos & Cooper Pharmaceuticals has been granted.
July 2014 — Chief Executive Officer wins coveted award in South Australia’s Tall Poppy Campaign
June 2014 — We have moved!
Boulos & Cooper Pharmaceuticals has moved into the Adelaide Business Hub on Todd Street, Port Adelaide.
April 2014 — Boulos & Cooper Pharmaceuticals gets exclusive licence
Boulos & Cooper Pharmaceuticals enters into an exclusive and perpetual licence agreement for the research, development and commercialisation of intellectual property owned by the Chief Executive Officer.
March 2014 — Radio Adelaide interviews Chief Executive Officer
March 2014 — Chief Executive Officer features in Flinders NanoCentre News
March 2014 — Chief Executive Officer raises $825 via donations to register Boulos & Cooper Pharmaceuticals
November 2012 — Chief Executive Officer talks to Channel 10 News